Business Description
Marksans Pharma Ltd
ISIN : INE750C01026
Compare
Compare
Traded in other countries / regions
MARKSANS.India IPO Date
2002-01-21Description
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.44 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | 0.36 | |||||
| Interest Coverage | 31.63 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 13.17 | |||||
| Beneish M-Score | -2.32 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.8 | |||||
| 3-Year EBITDA Growth Rate | 10.4 | |||||
| 3-Year EPS without NRI Growth Rate | 4.5 | |||||
| 3-Year FCF Growth Rate | -47.2 | |||||
| 3-Year Book Growth Rate | 28.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 24.18 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 17.88 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 14.55 | |||||
| 9-Day RSI | 22.62 | |||||
| 14-Day RSI | 28.94 | |||||
| 6-1 Month Momentum % | 70.39 | |||||
| 12-1 Month Momentum % | 96.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.68 | |||||
| Quick Ratio | 2.97 | |||||
| Cash Ratio | 1.53 | |||||
| Days Inventory | 207.34 | |||||
| Days Sales Outstanding | 74.53 | |||||
| Days Payable | 81.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.24 | |||||
| Dividend Payout Ratio | 0.08 | |||||
| 3-Year Dividend Growth Rate | 71 | |||||
| Forward Dividend Yield % | 0.24 | |||||
| 5-Year Yield-on-Cost % | 2.82 | |||||
| 3-Year Average Share Buyback Ratio | -3.5 | |||||
| Shareholder Yield % | -0.7 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 52.9 | |||||
| Operating Margin % | 18.06 | |||||
| Net Margin % | 14.61 | |||||
| FCF Margin % | 0.91 | |||||
| ROE % | 16.73 | |||||
| ROA % | 13.17 | |||||
| ROIC % | 19.59 | |||||
| 3-Year ROIIC % | 4.58 | |||||
| ROC (Joel Greenblatt) % | 32 | |||||
| ROCE % | 20.97 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 32.43 | |||||
| Forward PE Ratio | 24.58 | |||||
| PE Ratio without NRI | 32.43 | |||||
| Shiller PE Ratio | 57.29 | |||||
| PEG Ratio | 1.22 | |||||
| PS Ratio | 4.74 | |||||
| PB Ratio | 4.94 | |||||
| Price-to-Tangible-Book | 5.19 | |||||
| Price-to-Free-Cash-Flow | 521.95 | |||||
| Price-to-Operating-Cash-Flow | 48.87 | |||||
| EV-to-EBIT | 22.92 | |||||
| EV-to-EBITDA | 19.49 | |||||
| EV-to-Revenue | 4.55 | |||||
| EV-to-FCF | 500.69 | |||||
| Price-to-Projected-FCF | 3.88 | |||||
| Price-to-Median-PS-Value | 2.46 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.39 | |||||
| Price-to-Graham-Number | 2.74 | |||||
| Price-to-Net-Current-Asset-Value | 7.77 | |||||
| Price-to-Net-Cash | 217.94 | |||||
| Earnings Yield (Greenblatt) % | 4.36 | |||||
| FCF Yield % | 0.19 | |||||
| Forward Rate of Return (Yacktman) % | 20.94 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Marksans Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 23,754.67 | ||
| EPS (TTM) (₹) | 7.66 | ||
| Beta | 1.94 | ||
| Volatility % | 48.94 | ||
| 14-Day RSI | 28.94 | ||
| 14-Day ATR (₹) | 12.740884 | ||
| 20-Day SMA (₹) | 296.18 | ||
| 12-1 Month Momentum % | 96.26 | ||
| 52-Week Range (₹) | 130 - 358.7 | ||
| Shares Outstanding (Mil) | 453.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Marksans Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Marksans Pharma Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Marksans Pharma Ltd Frequently Asked Questions
What is Marksans Pharma Ltd(NSE:MARKSANS)'s stock price today?
The current price of NSE:MARKSANS is ₹248.45. The 52 week high of NSE:MARKSANS is ₹358.70 and 52 week low is ₹130.00.
When is next earnings date of Marksans Pharma Ltd(NSE:MARKSANS)?
The next earnings date of Marksans Pharma Ltd(NSE:MARKSANS) is 2025-02-13 Est..
Does Marksans Pharma Ltd(NSE:MARKSANS) pay dividends? If so, how much?
The Dividend Yield %  of Marksans Pharma Ltd(NSE:MARKSANS) is 0.24% (As of Today), Highest Dividend Payout Ratio of Marksans Pharma Ltd(NSE:MARKSANS) was 0.55. The lowest was 0.02. And the median was 0.05. The  Forward Dividend Yield % of Marksans Pharma Ltd(NSE:MARKSANS) is 0.24%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers